	US 11,732,307 B2
	Kit, device, and method for detecting bladder cancer
Makiko Yoshimoto, Kamakura (JP); Hiroko Sudo, Kamakura (JP); Satoko Kozono, Kamakura (JP); Junpei Kawauchi, Kamakura (JP); Takahiro Ochiya, Tokyo (JP); Hiroyuki Fujimoto, Tokyo (JP); Wataru Usuba, Tokyo (JP); and Juntaro Matsuzaki, Tokyo (JP)
Assigned to TORAY INDUSTRIES, INC., Tokyo (JP); and NATIONAL CANCER CENTER, Tokyo (JP)
Appl. No. 17/50,134
Filed by TORAY INDUSTRIES, INC., Tokyo (JP); and NATIONAL CANCER CENTER, Tokyo (JP)
PCT Filed Apr. 25, 2019, PCT No. PCT/JP2019/017536 § 371(c)(1), (2) Date Oct. 23, 2020, PCT Pub. No. WO2019/208671, PCT Pub. Date Oct. 31, 2019.
Claims priority of application No. 2018-084416 (JP), filed on Apr. 25, 2018.
Prior Publication US 2022/0275449 A1, Sep. 1, 2022
Int. Cl. C12Q 1/6886 (2018.01)

CPC C12Q 1/6886 (2013.01) [C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)]

9 Claims

1. A method for detecting bladder cancer, comprising:

measuring an expression level of miR-1185-1-3p in a sample from a human subject;

determining that the level of miR-1185-1-3p in the sample from the human subject is increased in comparison to a level of miR-1185-1-3p in a control sample from a human subject without bladder cancer;

determining that the human subject has bladder cancer based on the increased expression level of miR-1185-1-3p; and

treating the human subject for the bladder cancer;

wherein the sample is blood, serum, or plasma; and

wherein the treating comprises surgery, radiotherapy, chemotherapy, or a combination thereof.